

		<b>Conditions:</b>	Multiple Myeloma; Tumors
		<b>Intervention:</b>	Biological: Peptide Vaccine (MUC-1)
324	Recruiting	<a href="#">Efficacy and Safety Study of NeuVax(TM)(Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence</a>	
		<b>Condition:</b>	HER2 Negative Breast Cancer
		<b>Interventions:</b>	Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
325	Recruiting	<a href="#">Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist</a>	
		<b>Condition:</b>	Melanoma
		<b>Interventions:</b>	Drug: gp100; Drug: R848 gel; Drug: MAGE-3
326	Recruiting	<a href="#">Salvage Ovarian FANG Vaccine + Bevacizumab</a>	
		<b>Condition:</b>	Stage IIIC Ovarian Cancer
		<b>Interventions:</b>	Biological: FANG™ Vaccine; Drug: Bevacizumab
327	Recruiting	<a href="#">Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21</a>	
		<b>Condition:</b>	Recurrent Prostate Cancer
		<b>Intervention:</b>	Biological: Adenovirus/PSA Vaccine
328	Recruiting	<a href="#">To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid</a>	
		<b>Condition:</b>	Small Cell Lung Cancer
		<b>Interventions:</b>	Drug: Paclitaxel; Biological: Drug: Ad.p53-DC vaccines; Drug: All -trans Retinoic Acid (ATRA)
329	Completed	<a href="#">Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer</a>	
		<b>Conditions:</b>	Breast Cancer; Ovarian Cancer
		<b>Interventions:</b>	Biological: aldesleukin; Biological: p53 peptide vaccine; Procedure: in vitro-treated peripheral blood stem cell
330	Recruiting	<a href="#">Vaccine Therapy in Curative Resected Prostate Cancer Patients</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Biological: Dendritic cell vaccine
331	Completed	<a href="#">Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer</a>	
	Has	<b>Condition:</b>	Breast Cancer
		<b>Intervention:</b>	Biological: synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine
332	Completed	<a href="#">Multi-peptide Vaccine for Advanced Breast Cancer</a>	
		<b>Conditions:</b>	Breast Neoplasm; Breast Cancer; Cancer of the Breast; Carcinoma, Ductal
		<b>Intervention:</b>	Biological: hTERT/Survivin Multi-Peptide Vaccine
333	Completed	<a href="#">Vaccine Therapy in Treating Women With Metastatic Breast Cancer</a>	
		<b>Condition:</b>	Breast Cancer
		<b>Interventions:</b>	Biological: Detox-B adjuvant; Biological: THERATOPE STn-KLH vaccine; Biological: keyhole limpet hemocyanin;
334	Active, not recruiting	<a href="#">Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India</a>	
		<b>Conditions:</b>	Cervical Cancer; Cervical Precancerous Lesions
		<b>Intervention:</b>	Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
335	Unknown †	<a href="#">Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer</a>	
		<b>Conditions:</b>	Ovarian Cancer; Primary Peritoneal Cavity Cancer
		<b>Interventions:</b>	Biological: incomplete Freund's adjuvant; Biological: ovarian cancer peptide vaccine; Biological: sargramostim;
336	Completed	<a href="#">Vaccine Therapy in Treating Patients With Metastatic Cancer</a>	



		<b>Conditions:</b>	Lung Cancer; Adult Soft Tissue Sarcoma; Colorectal Cancer; Bone Cancer; Ovarian Sarcoma; Melanoma; Colon Cancer; Rectal Cancer; Breast Cancer; Eye Cancer; Uterine Sarcoma
		<b>Interventions:</b>	Drug: interleukin-2; Drug: MAGE-12 peptide vaccine; Drug: Montanide ISA-51
337	Completed	<a href="#">Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer</a>	
		<b>Conditions:</b>	Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
		<b>Interventions:</b>	Biological: fowlpox-NY-ESO-1 vaccine; Biological: recombinant vaccinia-NY-ESO-1 vaccine; Procedure: adjuvant therapy
338	Unknown †	<a href="#">Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer</a>	
		<b>Condition:</b>	Pancreatic Cancer
		<b>Interventions:</b>	Biological: sargramostim; Biological: telomerase peptide vaccine GV1001; Drug: capecitabine; Drug:
339	Active, not recruiting	<a href="#">Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer</a>	
		<b>Condition:</b>	Breast Cancer
		<b>Interventions:</b>	Biological: QS21; Biological: sialyl Lewis <sup>a</sup> -keyhole limpet hemocyanin conjugate vaccine; Other: immunoenzyme technique; Other: immunologic technique; Other: laboratory biomarker analysis
340	Completed	<a href="#">Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted</a>	
		<b>Conditions:</b>	H1N1 Influenza Virus; Invasive Solid Tumors
		<b>Interventions:</b>	Biological: adjuvanted A(H1N1) influenza vaccine; Biological: non-adjuvanted A(H1N1) influenza vaccine
341	Terminated	<a href="#">Vaccine Therapy in Treating Patients With Metastatic Solid Tumors</a>	
		<b>Condition:</b>	Unspecified Adult Solid Tumor, Protocol Specific
		<b>Interventions:</b>	Biological: recombinant fowlpox-B7.1 vaccine; Biological: recombinant fowlpox-TRICOM vaccine; Other:
342	Recruiting	<a href="#">Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)</a>	
		<b>Condition:</b>	Non Small Cell Lung Cancer (NSCLC)
		<b>Intervention:</b>	Biological: semi-allogeneic human fibroblasts (MRC-5) transfected with DNA
343	Unknown †	<a href="#">Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With</a>	
		<b>Condition:</b>	Colorectal Cancer
		<b>Interventions:</b>	Biological: ALVAC-CEA-B7.1 vaccine; Biological: tetanus toxoid; Drug: FOLFIRI regimen; Drug: fluorouracil;
344	Unknown †	<a href="#">Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma</a>	
		<b>Conditions:</b>	Breast Cancer; Malignant Melanoma
		<b>Intervention:</b>	Biological: DC vaccine
345	Recruiting	<a href="#">A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Biological: UV1 synthetic peptide vaccine and GM-CSF
346	Completed	<a href="#">Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Biological: MUC1-KLH vaccine/QS21
347	Completed	<a href="#">Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery</a>	
		<b>Condition:</b>	Colorectal Cancer
		<b>Interventions:</b>	Biological: BCG vaccine; Biological: autologous tumor cell vaccine; Drug: fluorouracil; Drug: leucovorin calcium;
348	Completed	<a href="#">Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer</a>	
		<b>Conditions:</b>	Breast Cancer; Lung Cancer; Ovarian Cancer



		<b>Interventions:</b>	Biological: HER-2/neu peptide vaccine; Biological: sargramostim
349	Recruiting	<a href="#">Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood</a>	
		<b>Conditions:</b>	Leukemia, Acute Myelogenous (AML); Leukemia, Acute Lymphocytic (ALL); Leukemia, Chronic Myelogenous (CML); Myelodysplastic Syndrome (MDS); Non-Hodgkin's Lymphoma (NHL)
		<b>Interventions:</b>	Drug: WT1 Peptide-Pulsed Dendritic Cells; Drug: Donor Lymphocytes; Drug: IL-4; Drug: KLH; Drug: WT1
350	Recruiting	<a href="#">Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer</a>	
		<b>Conditions:</b>	HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
		<b>Interventions:</b>	Biological: HER-2/neu peptide vaccine; Other: laboratory biomarker analysis
351	Completed	<a href="#">Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Interventions:</b>	Biological: QS21; Biological: TF(c)-KLH conjugate vaccine; Biological: Thomsen-Friedenreich antigen;
352	Completed	<a href="#">Vaccine Therapy in Preventing HPV in HIV-Positive Women in India</a>	
		<b>Conditions:</b>	Cervical Cancer; Nonneoplastic Condition; Precancerous Condition
		<b>Interventions:</b>	Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Genetic: DNA analysis;
353	Completed	<a href="#">Vaccine Therapy in Treating Patients With Advanced Kidney Cancer</a>	
		<b>Condition:</b>	Kidney Cancer
		<b>Interventions:</b>	Biological: dendritic cell vaccine therapy; Procedure: conventional surgery
354	Terminated	<a href="#">Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal</a>	
		<b>Conditions:</b>	Colorectal Cancer; Lung Cancer
		<b>Interventions:</b>	Drug: docetaxel; Drug: recombinant fowlpox-CEA(6D)/TRICOM vaccine; Drug: recombinant vaccinia-CEA(6D)-
355	Completed	<a href="#">Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer</a>	
		<b>Condition:</b>	Lung Cancer
		<b>Interventions:</b>	Biological: mutant p53 peptide pulsed dendritic cell vaccine; Procedure: adjuvant therapy
356	Completed	<a href="#">Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder</a>	
		<b>Condition:</b>	Bladder Cancer
		<b>Interventions:</b>	Biological: BCG vaccine; Biological: NY-ESO-1 peptide vaccine; Biological: sargramostim
357	Completed	<a href="#">A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer</a>	
		<b>Conditions:</b>	Ovarian Cancer; Peritoneal Cancer
		<b>Intervention:</b>	Biological: DCVac-L
358	Unknown †	<a href="#">Ovarian Cancer and Immune Response to Flu Vaccine</a>	
		<b>Condition:</b>	Ovarian Cancer
		<b>Intervention:</b>	Biological: The current season's trivalent killed influenza vaccine
359	Active, not recruiting	<a href="#">Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer</a>	
		<b>Condition:</b>	Lung Cancer
		<b>Intervention:</b>	Biological: therapeutic autologous dendritic cells
360	Completed	<a href="#">Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer</a>	
		<b>Conditions:</b>	Gastric Cancer; Head and Neck Cancer; Lymphoma; Lymphoproliferative Disorder; Nonneoplastic Condition
		<b>Interventions:</b>	Biological: EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine; Other: laboratory biomarker analysis; Other: pharmacological study
361	Active, not recruiting	<a href="#">A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer</a>	
		<b>Conditions:</b>	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer



		<b>Interventions:</b>	Biological: OC-L/Montanide ISA 51 VG; Biological: Ampligen; Biological: Prevnar
362	Completed	<a href="#">HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer</a>	
		<b>Conditions:</b>	Breast Cancer; Lung Cancer; Ovarian Cancer
		<b>Interventions:</b>	Biological: HER-2/neu peptide vaccine; Biological: sargramostim
363	Completed	<a href="#">Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells</a>	
	Has	<b>Condition:</b>	Prostate Cancer
		<b>Interventions:</b>	Biological: vaccine vehicle only; Biological: DC/LNCAp
364	Completed	<a href="#">Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence</a>	
		<b>Condition:</b>	Breast Cancer
		<b>Interventions:</b>	Biological: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine; Biological: QS21
365	Completed	<a href="#">Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic)</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine
366	Active, not recruiting	<a href="#">PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Biological: Peptide Vaccine
367	Recruiting	<a href="#">Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies</a>	
		<b>Condition:</b>	Malignant Neoplasm
		<b>Interventions:</b>	Biological: aldesleukin; Drug: fludarabine phosphate; Drug: cyclophosphamide; Other: laboratory biomarker
368	Not yet recruiting	<a href="#">Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects</a>	
		<b>Conditions:</b>	Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; High Grade Glioma
		<b>Interventions:</b>	Biological: Dendritic Cell Vaccine; Biological: Tumor Lysate; Other: Imiquimod; Procedure: Leukapheresis
369	Completed	<a href="#">Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Biological: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
370	Completed	<a href="#">Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma</a>	
	Has	<b>Condition:</b>	Renal Cell Carcinoma
		<b>Interventions:</b>	Biological: incomplete Freund's adjuvant; Biological: von Hippel-Lindau peptide vaccine
371	Completed	<a href="#">Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer</a>	
		<b>Conditions:</b>	Non-Small-Cell Lung Carcinoma; Lung Cancer; Pulmonary Cancer
		<b>Intervention:</b>	Biological: HSPPC-96
372	Completed	<a href="#">Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No</a>	
		<b>Condition:</b>	Breast Cancer
		<b>Intervention:</b>	Biological: OCPM Immunotherapeutic Vaccine
373	Completed	<a href="#">A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy</a>	
		<b>Condition:</b>	Breast Cancer



		<b>Intervention:</b>	Biological: MVA-BN-HER2
374	Recruiting	<a href="#">Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy</a>	
		<b>Conditions:</b>	Adenocarcinoma of the Bladder; Recurrent Bladder Cancer; Squamous Cell Carcinoma of the Bladder; Stage 0 Bladder Cancer; Stage I Bladder Cancer; Stage II Bladder Cancer; Stage III Bladder Cancer; Transitional Cell Carcinoma of the Bladder
		<b>Interventions:</b>	Procedure: conventional surgery; Biological: recombinant fowlpox-TRICOM vaccine
375	Recruiting	<a href="#">Vaccine Therapy in Treating Patients With Ductal Carcinoma In Situ of the Breast</a>	
		<b>Condition:</b>	Breast Cancer
		<b>Interventions:</b>	Biological: HER-2/neu peptide vaccine; Biological: therapeutic autologous dendritic cells
376	Completed	<a href="#">Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Biological: pTVG-HP with rhGM-CSF
377	Active, not recruiting	<a href="#">Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFN <math>\alpha</math>-2b in Metastatic Renal Cell Carcinoma (RCC) Patients</a>	
		<b>Condition:</b>	Metastatic Renal Cell Carcinoma
		<b>Interventions:</b>	Biological: DC vaccine; Drug: Bevacizumab; Biological: IL-2; Biological: IFN
378	Terminated	<a href="#">Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer</a>	
		<b>Condition:</b>	Lung Cancer
		<b>Interventions:</b>	Drug: autologous tumor cell vaccine; Drug: therapeutic autologous dendritic cells; Procedure: adjuvant therapy;
379	Recruiting	<a href="#">A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma</a>	
		<b>Conditions:</b>	Nasopharyngeal Cancer; Epstein Barr Virus Infections
		<b>Intervention:</b>	Drug: MVA-EBNA1/LMP2 vaccine
380	Active, not recruiting	<a href="#">MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Drug: MUC_1
381	Completed	<a href="#">Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors</a>	
		<b>Conditions:</b>	Breast Cancer; Esophageal Cancer; Gastric Cancer; Lung Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
		<b>Interventions:</b>	Biological: ALVAC-CEA vaccine; Biological: aldesleukin; Biological: sargramostim; Biological: vaccinia-CEA
382	Completed	<a href="#">Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer</a>	
		<b>Conditions:</b>	Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic
		<b>Interventions:</b>	Biological: allogeneic tumor cell vaccine; Biological: autologous tumor cell vaccine; Biological: recombinant interferon alfa; Biological: recombinant interferon gamma; Biological: sargramostim; Drug: cyclophosphamide
383	Recruiting	<a href="#">Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia</a>	
		<b>Conditions:</b>	Cervical Cancer; Precancerous Condition
		<b>Interventions:</b>	Biological: TA-HPV; Biological: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine; Drug: imiquimod
384	Completed	<a href="#">Tumor Cell Vaccine in Treating Patients With Advanced Cancer</a>	
		<b>Condition:</b>	Unspecified Adult Solid Tumor, Protocol Specific
		<b>Interventions:</b>	Biological: filgrastim; Biological: recombinant interferon gamma; Biological: tumor cell lysate vaccine therapy
385	Completed	<a href="#">Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer</a>	



		<b>Condition:</b>	Breast Cancer
		<b>Interventions:</b>	Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine; Biological: recombinant vaccinia-CEA(6D)-TRICOM vaccine; Biological: sargramostim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel;
386	Unknown †	<a href="#">Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer</a>	
		<b>Condition:</b>	Pancreatic Cancer
		<b>Interventions:</b>	Biological: Cetuximab; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine;
387	Recruiting	<a href="#">Dendritic Cell Vaccine for Patients With Brain Tumors</a>	
		<b>Conditions:</b>	Glioma; Anaplastic Astrocytoma; Anaplastic Astro-oligodendroglioma; Glioblastoma
		<b>Interventions:</b>	Biological: autologous tumor lysate-pulsed DC vaccination; Biological: Tumor lysate-pulsed DC vaccination+0.2% resiquimod; Biological: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
388	Active, not recruiting	<a href="#">A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen</a>	
		<b>Conditions:</b>	Melanoma; Sarcoma; Gastrointestinal Stromal Tumor (GIST); Head and Neck Cancer; Transitional Cell Carcinoma; Prostate Cancer
		<b>Intervention:</b>	Biological: Mixed Bacterial Vaccine (MBV)
389	Terminated	<a href="#">Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma</a>	
	Has	<b>Conditions:</b>	Metastatic Melanoma; Skin Cancer
		<b>Interventions:</b>	Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes; Biological: ALVAC MART-1 Vaccine; Biological: aldesleukin; Drug: cyclophosphamide; Drug: fludarabine phosphate
390	Completed	<a href="#">Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Interventions:</b>	Biological: aldesleukin; Biological: recombinant fowlpox-prostate specific antigen vaccine; Biological: recombinant
391	Active, not recruiting	<a href="#">Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer</a>	
		<b>Condition:</b>	Metastatic Pancreatic Cancer
		<b>Intervention:</b>	Biological: KLH-pulsed autologous dendritic cell vaccine
392	Completed	<a href="#">Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer</a>	
		<b>Conditions:</b>	Breast Cancer; Colorectal Cancer; Lung Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol
		<b>Interventions:</b>	Biological: denileukin diftitox; Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine; Biological: therapeutic autologous dendritic cells
393	Completed	<a href="#">Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer</a>	
		<b>Condition:</b>	Breast Cancer
		<b>Interventions:</b>	Biological: therapeutic autologous dendritic cells; Biological: trastuzumab; Drug: vinorelbine ditartrate
394	Terminated	<a href="#">S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer</a>	
		<b>Conditions:</b>	Brain Tumors; Gastric Cancer; Ovarian Cancer; Prostate Cancer
		<b>Interventions:</b>	Biological: KLH; Biological: GMCSF
395	Recruiting	<a href="#">Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: autologous tumor cell vaccine; Biological: sargramostim; Biological: therapeutic autologous dendritic
396	Withdrawn	<a href="#">Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer</a>	
		<b>Condition:</b>	Liver Cancer
		<b>Interventions:</b>	Biological: alpha fetoprotein adenoviral vector vaccine; Biological: alpha fetoprotein plasmid DNA vaccine; Biological: sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant
397	Completed	<a href="#">Phase IIIb Randomized Controlled Study of BLP25 Liposome Vaccine for Immunotherapy of Non-Small Cell Lung Cancer</a>	
		<b>Conditions:</b>	Lung Neoplasms; Carcinoma, Non-Small-Cell Lung



		<b>Interventions:</b> Biological: BLP25 Liposome Vaccine plus best supportive care; Other: Best Supportive Care (BSC)
398	Active, not recruiting	<u>Vaccine Therapy in Treating Patients With Kidney Cancer</u>
		<b>Condition:</b> Kidney Cancer
		<b>Interventions:</b> Biological: human prostate-specific membrane antigen plasmid DNA vaccine; Biological: mouse prostate-specific
399	Recruiting	<u>Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide</u>
		<b>Condition:</b> B-cell Chronic Lymphocytic Leukemia
		<b>Interventions:</b> Biological: B-CLL Vaccine; Drug: Lenalidomide
400	Suspended	<u>Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma</u>
		<b>Conditions:</b> Neuroblastoma; Sarcoma; Rhabdomyosarcoma-Embryonal; Rhabdomyosarcoma- Alveolar; Neuroectodermal Tumors, Primitive, Peripheral
		<b>Interventions:</b> Drug: Tumor Purged/CD25 Depleted Lymphocytes; Biological: Tumor Purged/CD25 Depleted Lymphocytes with
401	Unknown †	<u>Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma</u>
		<b>Condition:</b> Multiple Myeloma and Plasma Cell Neoplasm
		<b>Interventions:</b> Biological: pneumococcal polyvalent vaccine; Drug: lenalidomide
402	Completed	<u>Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer</u>
		<b>Conditions:</b> Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
		<b>Interventions:</b> Biological: MUC1-KLH conjugate vaccine; Biological: MUC1-KLH vaccine/QS21; Biological: QS21
403	Recruiting	<u>NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma</u>
		<b>Condition:</b> Unresectable or Metastatic Melanoma
		<b>Interventions:</b> Biological: Ipilimumab plus NY-ESO-1 OLP4 Vaccine; Biological: Ipilimumab plus NY-ESO-1 Protein Vaccine
404	Active, not recruiting	<u>Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer</u>
		<b>Condition:</b> Breast Cancer
		<b>Interventions:</b> Drug: Docetaxel; Biological: Familmarev; Biological: Inalimarev; Biological: Sargramostim
405	Active, not recruiting	<u>Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer</u>
		<b>Condition:</b> Prostate Cancer
		<b>Intervention:</b> Biological: autologous dendritic cell vaccine (DC/PC3)
406	Completed	<u>Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma</u>
		<b>Condition:</b> Risk for Colorectal Cancer
		<b>Intervention:</b> Biological: MUC1 - Poly ICLC
407	Unknown †	<u>Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer</u>
		<b>Condition:</b> Lung Cancer
		<b>Interventions:</b> Biological: EP-2101; Biological: incomplete Freund's adjuvant
408	Completed	<u>Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in</u>
		<b>Condition:</b> Lung Cancer
		<b>Interventions:</b> Biological: monoclonal antibody 11D10 anti-idiotype vaccine; Biological: monoclonal antibody 3H1 anti-idiotype
409	Not yet recruiting	<u>C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer</u>
		<b>Condition:</b> Breast Cancer
		<b>Interventions:</b> Biological: Adenovirus-p53 transduced dendritic cell vaccine; Drug: 1-methyl-D-tryptophan; Radiation: Carbon C 11 alpha-methyltryptophan
410	Unknown †	<u>Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection</u>
		<b>Condition:</b> Neoplasms



		<b>Intervention:</b>	Other: Immune profiling and DC vaccine
411	Completed Has	<a href="#">Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females</a>	
		<b>Conditions:</b>	Cervical Cancer; Papillomavirus Infection
		<b>Interventions:</b>	Biological: GSK Biologicals HPV 16/18 vaccine 580299 (Cervarix™); Biological: Gardasil® (Merck & Co. Inc); Biological: Placebo
412	Completed	<a href="#">Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma</a>	
		<b>Condition:</b>	Multiple Myeloma and Plasma Cell Neoplasm
		<b>Interventions:</b>	Biological: CMV pp65 peptide; Biological: hTERT I540/R572Y/D988Y multi-peptide vaccine; Biological: pneumococcal polyvalent vaccine; Biological: survivin Sur1M2 peptide vaccine
413	Terminated Has	<a href="#">Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic</a>	
		<b>Conditions:</b>	Kidney Cancer; Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific
		<b>Interventions:</b>	Biological: aldesleukin; Biological: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes; Biological: autologous dendritic cell-adenovirus p53 vaccine; Biological: filgrastim; Drug: cyclophosphamide; Drug:
414	Active, not recruiting	<a href="#">CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1</a>	
		<b>Condition:</b>	NY-ESO-1-expressing Tumors
		<b>Interventions:</b>	Biological: Vaccine only; Biological: Vaccine + cyclophosphamide
415	Unknown †	<a href="#">Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma</a>	
		<b>Conditions:</b>	Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer
		<b>Interventions:</b>	Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine; Biological: sargramostim; Drug:
416	Terminated	<a href="#">Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer</a>	
		<b>Condition:</b>	Unspecified Adult Solid Tumor, Protocol Specific
		<b>Interventions:</b>	Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine; Biological: recombinant vaccinia-CEA(6D)-TRICOM vaccine; Biological: sargramostim; Other: laboratory biomarker analysis
417	Active, not recruiting	<a href="#">Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma</a>	
		<b>Conditions:</b>	Recurrent Melanoma; Stage IV Melanoma
		<b>Interventions:</b>	Drug: cyclophosphamide; Biological: aldesleukin; Biological: autologous tumor cell vaccine; Other: laboratory
418	Completed	<a href="#">Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer</a>	
		<b>Conditions:</b>	Adenocarcinoma of the Prostate; Recurrent Prostate Cancer
		<b>Interventions:</b>	Biological: PSA:154-163(155L) peptide vaccine; Biological: incomplete Freund's adjuvant; Other: laboratory
419	Suspended	<a href="#">Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma</a>	
		<b>Conditions:</b>	Diffuse Intrinsic Pontine Glioma; Glioblastoma Multiforme; Adult Glioblastoma
		<b>Interventions:</b>	Biological: Tumor Lysate Vaccine; Drug: Imiquimod; Radiation: Radiation therapy
420	Completed	<a href="#">Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination</a>	
		<b>Condition:</b>	Cervical Cancer
		<b>Intervention:</b>	Drug: Licensed quadrivalent HPV vaccine, Gardasil
421	Terminated Has	<a href="#">Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma</a>	
		<b>Conditions:</b>	Metastatic Melanoma; Skin Cancer
		<b>Interventions:</b>	Drug: cyclophosphamide; Drug: fludarabine phosphate; Biological: Aldesleukin; Biological: ALVAC gp100 Vaccine; Biological: anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)
422	Recruiting	<a href="#">Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent/Post-</a>	
		<b>Conditions:</b>	High Risk WHO Grade II Glioma; Recurrent/Post-Chemotherapy WHO Grade II Glioma



		<b>Interventions:</b>	Biological: Tumor Lysate Vaccine; Drug: Imiquimod
423	Active, not recruiting	<a href="#">PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer</a>	
		<b>Condition:</b>	Adenocarcinoma
		<b>Interventions:</b>	Drug: PANVAC-V [Recombinant-Vaccinia-CEA (D609)/MUC-1(L93)/TRICOM]; Drug: PANVAC-F [Recombinant-Fowlpox-CEA (D609)/MUC-1(L93)/TRICOM]; Drug: Leukine (Sargramostim)
424	Terminated	<a href="#">GVAX® Vaccine for Prostate Cancer vs Docetaxel &amp; Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Interventions:</b>	Biological: Immunotherapy with allogeneic prostate vaccine; Drug: Chemotherapy (Taxotere and prednisone)
425	Recruiting	<a href="#">Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After</a>	
		<b>Conditions:</b>	Nasopharyngeal Cancer; Epstein-Barr Virus Infections
		<b>Intervention:</b>	Biological: Recombinant Epstein-Barr Virus (EBV) Vaccine
426	Active, not recruiting	<a href="#">Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation</a>	
		<b>Conditions:</b>	Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
		<b>Interventions:</b>	Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine; Biological: sargramostim; Biological:
427	Completed	<a href="#">SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells</a>	
		<b>Conditions:</b>	Atypical Squamous Cells of Undetermined Significance; Cervical Cancer; High-grade Squamous Intraepithelial Lesion; Low-grade Squamous Intraepithelial Lesion
		<b>Interventions:</b>	Biological: HspE7; Other: placebo; Other: laboratory biomarker analysis
428	Active, not recruiting	<a href="#">Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms</a>	
		<b>Condition:</b>	Leukemia
		<b>Intervention:</b>	Biological: WT-1
429	Completed	<a href="#">Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia</a>	
		<b>Conditions:</b>	Cervical Cancer; Cervical Intraepithelial Neoplasia Grade 3; Human Papilloma Virus Infection
		<b>Interventions:</b>	Biological: HspE7; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis
430	Recruiting	<a href="#">Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)</a>	
		<b>Conditions:</b>	HPV16+; Cervical Intraepithelial Neoplasia (CIN 2/3)
		<b>Interventions:</b>	Biological: DNA vaccination; Device: Gene gun vaccine; Biological: intramuscular vaccination; Biological: intra-
431	Recruiting	<a href="#">Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma</a>	
		<b>Conditions:</b>	Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
		<b>Intervention:</b>	Biological: recombinant hsp110-gp100 chaperone complex vaccine
432	Recruiting	<a href="#">Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults</a>	
		<b>Condition:</b>	Herpes Zoster Vaccine
		<b>Interventions:</b>	Biological: Herpes zoster vaccine (GSK 1437173A); Drug: Placebo
433	Completed	<a href="#">Vaccine Therapy in Treating Patients With Metastatic Melanoma</a>	
		<b>Conditions:</b>	Recurrent Melanoma; Stage IV Melanoma
		<b>Interventions:</b>	Biological: recombinant fowlpox-TRICOM vaccine; Other: laboratory biomarker analysis
434	Withdrawn	<a href="#">Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia</a>	
		<b>Condition:</b>	Leukemia
		<b>Interventions:</b>	Biological: autologous tumor cell vaccine; Biological: rituximab; Drug: cyclophosphamide



435	Recruiting	<a href="#">HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda</a>	
		<b>Conditions:</b>	HPV6 and HPV18; Immunogenicity; HPV Vaccine; Cervical Cancer; Partial Vaccination
436	Unknown †	<a href="#">Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine</a>	
		<b>Conditions:</b>	Cervical Intraepithelial Neoplasia; Cervical Cancer
437	Unknown †	<a href="#">Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer</a>	
		<b>Condition:</b>	Kidney Cancer
438	Recruiting	<a href="#">Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma</a>	
		<b>Conditions:</b>	Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia With Nodal Disease
439	Recruiting	<a href="#">Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma</a>	
		<b>Interventions:</b>	Biological: dendritic cell vaccine therapy; Procedure: cryotherapy; Biological: pneumococcal polyvalent vaccine;
440	Active, not recruiting	<a href="#">Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma</a>	
		<b>Conditions:</b>	Sarcoma; Soft Tissue Sarcoma; Bone Sarcoma
441	Active, not recruiting	<a href="#">Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF</a>	
		<b>Interventions:</b>	Biological: Dendritic Cells Vaccine; Biological: Lysate of Tumor; Drug: Gemcitabine; Other: Imiquimod;
442	Recruiting	<a href="#">Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF</a>	
		<b>Condition:</b>	Renal Cancer
443	Completed	<a href="#">A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women (V501-019 AM4, EXT1, EXT2 [AM1])</a>	
		<b>Interventions:</b>	Biological: Dendritic Cell Tumor Fusion Vaccine; Drug: Granulocyte Macrophage Colony Stimulating Factor (GM-Comparator: Placebo
444	Recruiting	<a href="#">Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer</a>	
		<b>Conditions:</b>	Healthy; Papillomavirus Infection
445	Unknown †	<a href="#">PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer</a>	
		<b>Interventions:</b>	Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine; Biological: Comparator: Placebo
446	Recruiting	<a href="#">Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy</a>	
		<b>Conditions:</b>	Recurrent Neuroendocrine Carcinoma of the Skin; Stage I Neuroendocrine Carcinoma of the Skin; Stage II Neuroendocrine Carcinoma of the Skin; Stage III Neuroendocrine Carcinoma of the Skin; Stage IV
447	Recruiting	<a href="#">Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma</a>	
		<b>Interventions:</b>	Biological: interleukin-12 gene; Biological: electroporation-mediated plasmid DNA vaccine therapy; Other:
448	Recruiting	<a href="#">Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma</a>	
		<b>Conditions:</b>	Prostate Cancer; Prostate Neoplasm
449	Recruiting	<a href="#">Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy</a>	
		<b>Interventions:</b>	Drug: rV-PSA; Drug: rF-PSA; Drug: rV-B7.1
450	Recruiting	<a href="#">Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma</a>	
		<b>Condition:</b>	Neoplasms
451	Recruiting	<a href="#">Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma</a>	
		<b>Intervention:</b>	Biological: trivalent influenza vaccine
452	Unknown †	<a href="#">Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma</a>	
		<b>Conditions:</b>	Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
453	Recruiting	<a href="#">Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma</a>	
		<b>Interventions:</b>	Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine; Biological: autologous